Description
Everolimusisaninhibitorofmammaliantargetofrapamycin1(mTOR1)thatisusedclinicallyforitsimmunosuppressiveactivityinrenaltransplantrecipientsandiscurrentlyinclinicaltrialsexploringitsanticancerchemotherapeuticactivity.Innasopharyngealcarcinomacells,everolimusinducesapoptosisandautophagy,inhibitingcellgrowth.Inesophagealcancercells,everolimusdecreasesexpressionofmTORtargetsp70S6KandS6,increasingcelldamageanddecreasingcellproliferation.Inanimalmodelsofexperimentalautoimmuneuveoretinitis(EAU),everolimusdecreaseslevelsofTh1,Th4,andTh17cytokinesandincreaseslevelsofTregcells,attenuatingdiseasepathology.Additionally,everolimusexhibitsnephroprotectivebenefitatlowdoses,decreasingadriamycin-inducedproteinuriaandimprovingrenalfunctioninanimalmodelsofnephroticsyndrome.
References
SendurMA,ZenginN,AksoyS,etal.Everolimus:anewhopeforpatientswithbreastcancer.CurrMedResOpin.2014Jan;30(1):75-87.PMID:24050600.
CaiY,XiaQ,SuQ,etal.mTORinhibitorRAD001(everolimus)inducesapoptotic,notautophagiccelldeath,inhumannasopharyngealcarcinomacells.IntJMolMed.2013Apr;31(4):904-12.PMID:23426850.
HennigM,BauerD,WasmuthS,etal.Everolimusimprovesexperimentalautoimmuneuveoretinitis.ExpEyeRes.2012Dec;105:43-52.PMID:23059401.
RamadanR,FaourD,AwadH,etal.Earlytreatmentwitheverolimusexertsnephroprotectiveeffectinratswithadriamycin-inducednephroticsyndrome.NephrolDialTransplant.2012Jun;27(6):2231-41.PMID:22036940.
WangZG,FukazawaT,NishikawaT,etal.RAD001offersatherapeuticinterventionthroughinhibitionofmTORasapotentialstrategyforesophagealcancer.OncolRep.2010Apr;23(4):1167-72.PMID:20204306.
KahanBD,KochSM.Currentimmunosuppressantregimens:considerationsforcriticalcare.CurrOpinCritCare.2001Aug;7(4):242-50.PMID:11571421.